Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 9;41(15):2596–2604. doi: 10.1016/j.vaccine.2023.03.006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Participants of the COVID-19 Community Research Partnership Study included in analysis of vaccine effectiveness using serologic data. a. Among 29,187 adults enrolled in the study via one of the 4 included health systems in this analysis, 27,535 did not report a previous COVID-19 diagnosis at the time of study enrollment. Of these, 19,235 were sent at least one serology kit between March 1, 2021 and October 31, 2021, and 17,235 returned one or more serology dried blood spot specimens. b. Among 16,675 participants who returned ≥1 serology kits after March 1, 2021, 15,125 returned at least 2 serology kits. c. Among the 676 participants excluded, 625 were excluded because they only received one dose or a non-mRNA vaccine; the remaining 51 participants had an unknown vaccination status. d. Test kit results were excluded based on the timing of vaccination status if a participant was categorized as “partially vaccinated” or having received a third dose at the collection date for the previous negative test.